Lansforsakringar Fondforvaltning’s Vertex Pharmaceuticals VRTX Stock Holding History

Lansforsakringar Fondforvaltning’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$37.4M	Sell	83,846 -7,980	-9%	-$3.72M	0.2%	100
2025 Q4	$41.6M	Sell	91,826 -54,737	-37%	-$23.6M	0.21%	95
2025 Q3	$57.4M	Buy	146,563 +5,273	+4%	+$2.2M	0.3%	63
2025 Q2	$62.9M	Buy	141,290 +4,979	+4%	+$2.29M	0.36%	54
2025 Q1	$66.1M	Sell	136,311 -8,397	-6%	-$3.91M	0.41%	47
2024 Q4	$58.3M	Buy	+144,708	New	+$67.1M	0.33%	59

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Lansforsakringar Fondforvaltning's VRTX Position: Q1 2026 in Review

Lansforsakringar Fondforvaltning reduced its Vertex Pharmaceuticals (VRTX) stake by 8.7% in Q1 2026, selling an estimated $3.72M and leaving 83,846 shares worth $37.4M. The position accounts for 0.2% of the portfolio, ranked #100.

Lansforsakringar Fondforvaltning first reported a position in VRTX in Q4 2024 and has held it in 6 quarters since. The position peaked at $66.1M in Q1 2025. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

Lansforsakringar Fondforvaltning held 83,846 shares of Vertex Pharmaceuticals worth $37.4M as of Q1 2026.
Lansforsakringar Fondforvaltning sold 7,980 Vertex Pharmaceuticals shares in Q1 2026, an estimated $3.72M.
Vertex Pharmaceuticals made up 0.2% of Lansforsakringar Fondforvaltning's portfolio in Q1 2026, its #100 holding.
Lansforsakringar Fondforvaltning first reported a position in Vertex Pharmaceuticals in Q4 2024 and has held it in 6 quarters since.
Lansforsakringar Fondforvaltning's Vertex Pharmaceuticals position peaked at $66.1M in Q1 2025.
1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Lansforsakringar Fondforvaltning's 13F filing for Q1 2026, filed 23 Apr 2026.